{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T07:51:20Z","timestamp":1791273080484,"version":"4.1.0"},"reference-count":37,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"10","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Jiangsu Provincial Key Research and Development Program","award":["BE2023797"],"award-info":[{"award-number":["BE2023797"]}]},{"name":"Basic Research Program of Jiangsu","award":["BK20243061"],"award-info":[{"award-number":["BK20243061"]}]},{"name":"National Natural Science Foundation of China","award":["82270767"],"award-info":[{"award-number":["82270767"]}],"id":[{"id":"https:\/\/ror.org\/01h0zpd94","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["JASN"],"published-print":{"date-parts":[[2026,10]]},"abstract":"\n Key Points<\/jats:title>\n \n \n \n \n This study evaluated the safety and efficacy of\n B<\/jats:italic>\n -cell maturation antigen-CD19 dual-targeted chimeric antigen receptor-\n T<\/jats:italic>\n \u2013cell therapy for patients with relapsed\/refractory AL amyloidosis.\n <\/jats:p>\n <\/jats:list-item>\n \n \n B<\/jats:italic>\n -cell maturation antigen-CD19 dual-targeted chimeric antigen receptor-\n T<\/jats:italic>\n \u2013cell therapy was well tolerated and no dose limiting toxicity occurred.\n <\/jats:p>\n <\/jats:list-item>\n \n \n Single-cell analysis confirmed\n B<\/jats:italic>\n -cell maturation antigen-CD19 chimeric antigen receptor-\n T<\/jats:italic>\n \u2013cell enabled complete elimination of pathogenic plasma and\n B<\/jats:italic>\n cells and promoted immune reconstitution.\n <\/jats:p>\n <\/jats:list-item>\n <\/jats:list>\n <\/jats:p>\n <\/jats:sec>\n \n Background<\/jats:title>\n \n The potential efficacy of chimeric antigen receptor (CAR)-\n T<\/jats:italic>\n cells for the treatment of relapsed\/refractory systemic light chain (AL) amyloidosis remains elusive. This study aimed to investigate the efficacy and safety of\n B<\/jats:italic>\n -cell maturation antigen (BCMA)-CD19 dual-targeted CAR-\n T<\/jats:italic>\n \u2013cell therapy in patients with refractory\/relapsed AL amyloidosis in a single-center exploratory trial.\n <\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n \n The key eligibility criteria of this trial were patients with AL amyloidosis and at least one major organ involvement who were refractory to or had relapsed from at least two lines of therapy. The primary outcome was the safety of CAR-\n T<\/jats:italic>\n therapy. All eligible patients received a single infusion of 0.3\u00d710\n 6<\/jats:sup>\n \/kg the BCMA-CD19 dual-targeted CAR-\n T<\/jats:italic>\n cells after preconditioning with fludarabine (30 mg\/m\n 2<\/jats:sup>\n per day for 3 days) and cyclophosphamide (300 mg\/m\n 2<\/jats:sup>\n per day for 3 days).\n <\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Notably, six patients with refractory\/relapsed AL amyloidosis were enrolled, all of whom had kidney involvement, and one of whom had cardiac involvement with Mayo stage 3a disease. After a median follow-up of 640 (range, 563\u2013745) days, all six patients achieved hematologic complete response (100%, 95% confidence interval, 54% to 100%) and renal response (100%, 95% confidence interval, 54% to 100%). The median time to hematologic response and renal response were 9 (interquartile range, 6\u201311) and 75 (interquartile range, 18\u2013180) days, respectively. One patient relapsed at month 6, while the other patients remained in remission. Grade 1 cytokine release syndrome occurred in two patients, and no immune effector cell\u2013associated neurotoxicity syndrome was identified. Pneumonia occurred in two of the six patients. One patient had grade 3 urticaria and grade 2 AKI. One patient developed acute promyelocytic leukemia 15 months post\u2013CAR-\n T<\/jats:italic>\n \u2013cell therapy. Single-cell RNA\/\n B<\/jats:italic>\n -cell receptor sequencing confirmed that BCMA-CD19 dual-targeted CAR-\n T<\/jats:italic>\n cells enabled the comprehensive clearance of pathogenic plasma cells and aberrant\n B<\/jats:italic>\n cells, while also promoting endogenous immune reconstitution in AL amyloidosis.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n \n This study provides preliminary evidence for the feasibility and tolerability of BCMA-CD19 dual-targeting CAR-\n T<\/jats:italic>\n \u2013cell therapy, and it showed promising activity in patients with relapsed\/refractory AL amyloidosis.\n <\/jats:p>\n <\/jats:sec>\n \n Clinical Trial registry name and registration number:<\/jats:title>\n ClinicalTrials.gov, NCT05978661.<\/jats:p>\n <\/jats:sec>","DOI":"10.1681\/asn.0000001096","type":"journal-article","created":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T16:24:47Z","timestamp":1775060687000},"page":"2236-2247","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["B-Cell Maturation Antigen-CD19 Dual-Targeted Chimeric Antigen Receptor-T\u2013Cell Therapy for Relapsed or Refractory AL Amyloidosis"],"prefix":"10.1681","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0243-9426","authenticated-orcid":false,"given":"Xianghua","family":"Huang","sequence":"first","affiliation":[{"name":"National Clinical Research Center for Kidney Diseases, Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-5523-4933","authenticated-orcid":false,"given":"Xiaomei","family":"Wu","sequence":"additional","affiliation":[{"name":"National Clinical Research Center for Kidney Diseases, Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6706-5237","authenticated-orcid":false,"given":"Wencui","family":"Chen","sequence":"additional","affiliation":[{"name":"National Clinical Research Center for Kidney Diseases, Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenshi","family":"Wang","sequence":"additional","affiliation":[{"name":"Shanghai Fosun Kairos Biotechnology Co., Ltd., Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0937-3949","authenticated-orcid":false,"given":"Weiwei","family":"Xu","sequence":"additional","affiliation":[{"name":"National Clinical Research Center for Kidney Diseases, Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinzhou","family":"Guo","sequence":"additional","affiliation":[{"name":"National Clinical Research Center for Kidney Diseases, Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinghua","family":"Zhao","sequence":"additional","affiliation":[{"name":"Shanghai Fosun Kairos Biotechnology Co., Ltd., Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaodong","family":"Xu","sequence":"additional","affiliation":[{"name":"National Clinical Research Center for Kidney Diseases, Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-3659-7512","authenticated-orcid":false,"given":"Chris","family":"Wang","sequence":"additional","affiliation":[{"name":"Shanghai Fosun Kairos Biotechnology Co., Ltd., Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aidong","family":"Shan","sequence":"additional","affiliation":[{"name":"Shanghai Fosun Kairos Biotechnology Co., Ltd., Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiawei","family":"Xu","sequence":"additional","affiliation":[{"name":"Shanghai Fosun Kairos Biotechnology Co., Ltd., Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6093-0726","authenticated-orcid":false,"given":"Zhihong","family":"Liu","sequence":"additional","affiliation":[{"name":"National Clinical Research Center for Kidney Diseases, Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,4,1]]},"reference":[{"issue":"10038","key":"B1-20261005","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1016\/S0140-6736(15)01274-X","article-title":"Systemic amyloidosis","volume":"387","author":"Wechalekar","year":"2016","journal-title":"Lancet."},{"issue":"24","key":"B2-20261005","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMra2304088","article-title":"Systemic light chain amyloidosis","volume":"390","author":"Sanchorawala","year":"2024","journal-title":"N Engl J Med."},{"issue":"1","key":"B3-20261005","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1080\/13506129.2022.2093635","article-title":"Guidelines for non-transplant chemotherapy for treatment of systemic AL amyloidosis: EHA-ISA working group","volume":"30","author":"Wechalekar","year":"2023","journal-title":"Amyloid."},{"issue":"6","key":"B4-20261005","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1016\/j.hoc.2020.08.001","article-title":"Systemic amyloidosis due to clonal plasma cell diseases","volume":"34","author":"Bianchi","year":"2020","journal-title":"Hematology Oncol Clin North Am"},{"issue":"5","key":"B5-20261005","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1056\/NEJMoa2403407","article-title":"Belantamab mafodotin, pomalidomide, and dexamethasone in multiple myeloma","volume":"391","author":"Dimopoulos","year":"2024","journal-title":"N Engl J Med."},{"issue":"10301","key":"B6-20261005","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/S0140-6736(21)01338-6","article-title":"Teclistamab, a B-cell maturation antigen x CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study","volume":"398","author":"Usmani","year":"2021","journal-title":"Lancet."},{"issue":"8","key":"B7-20261005","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N Engl J Med."},{"issue":"10297","key":"B8-20261005","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet."},{"issue":"9","key":"B9-20261005","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/s41408-022-00717-2","article-title":"High response rates with single-agent belantamab mafodotin in relapsed systemic AL amyloidosis","volume":"12","author":"Khwaja","year":"2022","journal-title":"Blood Cancer J."},{"issue":"8","key":"B10-20261005","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1182\/blood.2023022937","article-title":"Teclistamab in relapsed or refractory AL amyloidosis: a multinational retrospective case series","volume":"143","author":"Forgeard","year":"2024","journal-title":"Blood."},{"issue":"17","key":"B11-20261005","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1200\/JCO-24-02252","article-title":"Efficacy and safety of anti-B-cell maturation antigen chimeric antigen receptor T-cell for the treatment of relapsed and refractory AL amyloidosis","volume":"43","author":"Lebel","year":"2025","journal-title":"J Clin Oncol"},{"issue":"6","key":"B12-20261005","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1093\/jimmun\/vkaf008","article-title":"Can autoimmune disease be cured by deep CD19+ cell depletion?","volume":"214","author":"Suan","year":"2025","journal-title":"J Immunol."},{"issue":"6","key":"B13-20261005","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.1182\/blood-2003-09-3064","article-title":"Characterization of clonogenic multiple myeloma cells","volume":"103","author":"Matsui","year":"2004","journal-title":"Blood."},{"issue":"2","key":"B14-20261005","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1038\/leu.2016.211","article-title":"Differentiation stage of myeloma plasma cells: biological and clinical significance","volume":"31","author":"Paiva","year":"2017","journal-title":"Leukemia."},{"issue":"1","key":"B15-20261005","doi-asserted-by":"crossref","first-page":"3371","DOI":"10.1038\/s41467-024-47801-8","article-title":"Bispecific CAR T cell therapy targeting BCMA and CD19 in relapsed\/refractory multiple myeloma: a phase I\/II trial","volume":"15","author":"Shi","year":"2024","journal-title":"Nat Commun."},{"issue":"4","key":"B16-20261005","doi-asserted-by":"crossref","first-page":"e127684","DOI":"10.1172\/jci.insight.127684","article-title":"Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma","volume":"4","author":"Garfall","year":"2019","journal-title":"JCI Insight."},{"issue":"20","key":"B17-20261005","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1200\/JCO.21.01676","article-title":"Long-term Follow-Up of combination of B-Cell maturation antigen and CD19 chimeric antigen receptor T cells in multiple myeloma","volume":"40","author":"Wang","year":"2022","journal-title":"J Clin Oncol."},{"issue":"1","key":"B18-20261005","first-page":"67","article-title":"Systemic light chain amyloidosis, version 2.2023, NCCN clinical practice guidelines in oncology","volume":"21","author":"Kumar","year":"2023","journal-title":"J Natl Compr Canc Netw."},{"issue":"4","key":"B19-20261005","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant."},{"issue":"23","key":"B20-20261005","doi-asserted-by":"crossref","first-page":"5156","DOI":"10.1158\/1078-0432.CCR-22-0637","article-title":"Feasibility of a novel academic BCMA-CART (HBI0101) for the treatment of relapsed and refractory AL amyloidosis","volume":"28","author":"Kfir-Erenfeld","year":"2022","journal-title":"Clin Cancer Res."},{"issue":"12","key":"B21-20261005","doi-asserted-by":"crossref","first-page":"e003783","DOI":"10.1136\/jitc-2021-003783","article-title":"First report of CART treatment in AL amyloidosis and relapsed\/refractory multiple myeloma","volume":"9","author":"Oliver-Caldes","year":"2021","journal-title":"J Immunother Cancer."},{"issue":"11","key":"B22-20261005","doi-asserted-by":"crossref","first-page":"9627","DOI":"10.3390\/curroncol30110697","article-title":"Anti-B cell maturation antigen chimeric antigen receptor T cell therapy for the treatment of AL amyloidosis and concurrent relapsed\/refractory multiple myeloma: preliminary efficacy and safety","volume":"30","author":"Das","year":"2023","journal-title":"Curr Oncol."},{"issue":"4","key":"B23-20261005","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1038\/s44321-024-00043-z","article-title":"B cell lineage reconstitution underlies CAR-T cell therapeutic efficacy in patients with refractory myasthenia gravis","volume":"16","author":"Tian","year":"2024","journal-title":"EMBO Mol Med."},{"issue":"1","key":"B24-20261005","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s40164-023-00402-5","article-title":"Identification of potential resistance mechanisms and therapeutic targets for the relapse of BCMA CAR-T therapy in relapsed\/refractory multiple myeloma through single-cell sequencing","volume":"12","author":"Li","year":"2023","journal-title":"Exp Hematol Oncol."},{"key":"B25-20261005","doi-asserted-by":"crossref","first-page":"1063986","DOI":"10.3389\/fimmu.2022.1063986","article-title":"Secondary myeloid neoplasms after CD19 CAR T therapy in patients with refractory\/relapsed B-cell lymphoma: case series and review of literature","volume":"13","author":"Zhao","year":"2023","journal-title":"Front Immunol"},{"issue":"9","key":"B26-20261005","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1038\/s43018-024-00763-8","article-title":"Single-cell multiomic dissection of response and resistance to chimeric antigen receptor T cells against BCMA in relapsed multiple myeloma","volume":"5","author":"Rade","year":"2024","journal-title":"Nat Cancer."},{"issue":"35","key":"B27-20261005","doi-asserted-by":"crossref","first-page":"3978","DOI":"10.1200\/JCO.21.01992","article-title":"Management of immune-related adverse events in patients treated with chimeric antigen receptor T-cell therapy: ASCO guideline","volume":"39","author":"Santomasso","year":"2021","journal-title":"J Clin Oncol"},{"key":"B28-20261005","doi-asserted-by":"crossref","first-page":"104134","DOI":"10.1016\/j.critrevonc.2023.104134","article-title":"Infections in haematology patients treated with CAR-T therapies: a systematic review and meta-analysis","volume":"192","author":"Reynolds","year":"2023","journal-title":"Crit Rev Oncol Hematol."},{"issue":"1","key":"B29-20261005","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1182\/bloodadvances.2020002732","article-title":"Immune reconstitution and infectious complications following axicabtagene ciloleucel therapy for large B-cell lymphoma","volume":"5","author":"Baird","year":"2021","journal-title":"Blood Adv."},{"issue":"10","key":"B30-20261005","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1038\/s41409-022-01756-w","article-title":"Infectious complications, immune reconstitution, and infection prophylaxis after CD19 chimeric antigen receptor T-cell therapy","volume":"57","author":"Wudhikarn","year":"2022","journal-title":"Bone Marrow Transplant."},{"issue":"23","key":"B31-20261005","doi-asserted-by":"crossref","first-page":"5290","DOI":"10.1182\/bloodadvances.2021004603","article-title":"Humoral immune reconstitution after anti-BCMA CAR T-cell therapy in relapsed\/refractory multiple myeloma","volume":"5","author":"Wang","year":"2021","journal-title":"Blood Adv."},{"issue":"2","key":"B32-20261005","doi-asserted-by":"crossref","first-page":"31","DOI":"10.46989\/001c.115932","article-title":"Managing infection complications in the setting of chimeric antigen receptor T cell (CAR-T) therapy","volume":"6","author":"Ahmed","year":"2024","journal-title":"Clin Hematol Int."},{"issue":"20","key":"B33-20261005","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1182\/blood.2024024166","article-title":"Second primary malignancies after commercial CAR T-cell therapy: analysis of the FDA adverse events reporting system","volume":"143","author":"Elsallab","year":"2024","journal-title":"Blood."},{"issue":"20","key":"B34-20261005","doi-asserted-by":"crossref","first-page":"4690","DOI":"10.1158\/1078-0432.CCR-24-1798","article-title":"Second primary malignancies after CAR T-cell therapy: a systematic review and meta-analysis of 5,517 lymphoma and myeloma patients","volume":"30","author":"Tix","year":"2024","journal-title":"Clin Cancer Res"},{"issue":"22","key":"B35-20261005","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1056\/NEJMoa2401361","article-title":"Risk of second tumors and T-Cell lymphoma after CAR T-cell therapy","volume":"390","author":"Hamilton","year":"2024","journal-title":"N Engl J Med"},{"issue":"95","key":"B36-20261005","doi-asserted-by":"crossref","first-page":"eadj9730","DOI":"10.1126\/sciimmunol.adj9730","article-title":"Single-cell analysis of anti-BCMA CAR T cell therapy in patients with central nervous system autoimmunity","volume":"9","author":"Qin","year":"2024","journal-title":"Sci Immunol."},{"issue":"4","key":"B37-20261005","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1038\/s41571-021-00593-y","article-title":"Single-cell profiling of tumour evolution in multiple myeloma - opportunities for precision medicine","volume":"19","author":"Dutta","year":"2022","journal-title":"Nat Rev Clin Oncol."}],"container-title":["Journal of the American Society of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1681\/ASN.0000001096","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T20:00:33Z","timestamp":1791230433000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1681\/ASN.0000001096"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,1]]},"references-count":37,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1681\/asn.0000001096","relation":{},"ISSN":["1046-6673","1533-3450"],"issn-type":[{"value":"1046-6673","type":"print"},{"value":"1533-3450","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,1]]},"assertion":[{"value":"2025-12-26","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-27","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}